by Oscar Jofre | Feb 8, 2022 | Capital Markets, Capital Raising, KoreConX, News Releases
‘Father of the JOBS Act,’ Mr. Weild will join KoreConX to address a keynote on how Medtech is the new frontier to a successful capital raising NEW YORK, February 8, 2022 – KoreConX and its partner, Life Science Intelligence, are bringing together top...
by Oscar Jofre | Feb 7, 2022 | Capital Markets, Capital Raising, Regulation, SEC
It is essential to be familiar with the different regulations that govern how companies can raise capital in today’s business world. One important rule is Regulation S. This article will give you a basic overview of Regulation S, how it affects businesses, and...
by Oscar Jofre | Feb 2, 2022 | Capital Markets, Capital Raising
If your company is looking to raise funding, you’ve probably considered many options for doing so. Since the SEC introduced the outlines for Regulation A+ in the JOBS Act in 2012 and its subsequent amendments, companies are able to raise amounts up to $75...
by Oscar Jofre | Jan 26, 2022 | Capital Markets, Capital Raising, KoreConX, KorePartner, News Releases, Regulation
Medtech and Life Sciences main event will be held next March in California. KoreConX is one of the supporting sponsors. NEW YORK, January 26, 2022 – KoreConX is pleased to announce its partnership with LSI Emerging Medtech Summit 2022, which will be held March...
by Oscar Jofre | Jan 17, 2022 | Capital Markets, Capital Raising, KorePartner
This article was originally written by our KorePartners at StartEngine. You can view the post here. The high-speed world of startups, and the risks of investing in them, are well documented, but startup investing can be complicated and there is a lot of information...
by Oscar Jofre | Jan 14, 2022 | Capital Markets, Capital Raising, KorePartner
With the recent launch of the KoreConX all-in-one platform, KoreConX is happy to feature the partners contributing to its ecosystem. During the capital raising journey, many components must be in place to increase the potential for success. One of these...
